14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.47 $1.47 Thursday, 10th Nov 2022 EPZM stock ended at $1.47. During the day the stock fluctuated 0% from a day low at $1.47 to a day high of $1.47.
90 days $1.47 $1.47
52 weeks $0.411 $4.88

Historical Epizyme prices

Date Open High Low Close Volume
Oct 06, 2022 $1.47 $1.47 $1.47 $1.47 0
Oct 05, 2022 $1.47 $1.47 $1.47 $1.47 0
Oct 04, 2022 $1.47 $1.47 $1.47 $1.47 0
Oct 03, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 30, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 29, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 28, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 27, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 26, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 23, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 22, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 21, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 20, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 19, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 16, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 15, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 14, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 13, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 12, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 09, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 08, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 07, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 06, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 02, 2022 $1.47 $1.47 $1.47 $1.47 0
Sep 01, 2022 $1.47 $1.47 $1.47 $1.47 0
Click to get the best stock tips daily for free!

About Epizyme

Epizyme Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in pa... EPZM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT